A micro-cap AIM biotech valued at under £10m has just opened a Phase 2 trial in one of the most difficult corners of oncology. CRISM Therapeutics Corporation (LSE:CRTX) confirmed on 20 August 2026 that the first clinical site for its Phase 2 study of irinotecan-ChemoSeed in glioblastoma has been activated and patient recruitment has begun, more than two years after the company's May 2024 AIM listing.
The question for investors is whether a Business with no revenue, a 2025 loss of £1.9m and a Market Value of roughly £8.9m is being priced as a differentiated drug-delivery platform or simply as another cash-hungry small-cap. The coming months, culminating in treatment of the first patient, will go a long way towards answering that.
Latest development: first site live, recruitment under way in glioblastoma
CRISM's most recent material announcement came on 20 August 2026, a week after it reported completing the Site Initiation Visit at its lead NHS trial site. The update confirmed the site had been formally activated and the clinical team could begin identifying, screening and enrolling eligible patients, with the next key milestone being the successful treatment of the first patient.
Professor Christopher McConville, Chief Scientific Officer, called the activation "an important milestone for CRISM and the ChemoSeed programme". Professor Garth Cruickshank, Emeritus Professor of Neurosurgery at the University of Birmingham and a Scientific Advisory Board member, said opening the study "is a significant milestone in developing this novel treatment platform", noting that ChemoSeed delivers irinotecan directly into the tumour resection Margin during surgery, achieving high local concentrations while limiting systemic exposure.
The trial is an open-label Phase 2 study run in two parts, with Aixial Group as contract research organisation. The MHRA granted approval on 1 September 2025, and on 17 March 2026 the US FDA awarded Orphan Drug Designation for malignant glioma, broader than the glioblastoma-only indication originally requested, carrying seven years of US market exclusivity on approval, tax credits and fee exemptions.
The timetable has slipped: in April 2026 management guided to first patient dosing in the first half of the year. Recruitment is now open, but first dosing has not yet been announced.
Business overview: a locally delivered chemotherapy platform
CRISM Therapeutics is a clinical-stage drug-delivery company incorporated in the British Virgin Islands, with its scientific base in the UK and roots at the University of Birmingham. Its core asset is ChemoSeed, an implantable, biodegradable system that releases chemotherapy continuously into cancer tissue. The seeds are placed in the cavity left after surgical removal of a tumour, exposing residual cancer cells to sustained, high local drug concentrations while sparing the rest of the body the toxicity of systemic dosing.
The lead programme is irinotecan-ChemoSeed for glioblastoma, an aggressive brain cancer where standard care remains surgery followed by radiotherapy and temozolomide. The second, docetaxel-ChemoSeed for prostate cancer, is preclinical: on 21 April 2026 the company reported a 58% reduction in tumour Volume at the most effective dose in a prostate cancer model, with a clear dose-response relationship and no tolerability problems. Management has invited partnering discussions on this asset.
The company has no product revenue. Its value rests on clinical progress, patents granted in Europe and Japan, and grant funding, with licensing or partnering the long-term route to income.
FY2025 results: loss widens as trial preparation accelerates
Final results for the year ended 31 December 2025, published on 26 June 2026, showed no revenue. Research and Development spending was £908,000 as the company prepared for the Phase 2 study. The operating loss rose to £1.878m from £582,000 in 2024, and the loss after tax widened to £1.903m from £607,000. Loss per share was 5.1p against 1.8p.
Cash at 31 December 2025 stood at £1.128m, down from £1.282m, after fundraises of £874,021 in June 2025 and £1.06m in December 2025. Net Assets were £1.416m. The directors stated they had a reasonable expectation of adequate resources to continue, citing post-period funding.
That funding arrived in May and June 2026. A placing of £2.5m at 10p per share, a 13% discount to the 11.5p closing price on 22 May 2026, was described as significantly oversubscribed; with a retail offer, the Annual Report puts the total at £2.745m. Each new share carried a Warrant exercisable at 15p until 16 December 2027. Innovate UK then awarded an £896,088 grant on 4 June 2026, covering 70% of a £1.28m project to fund Part 1 of the trial, alongside a £99,902 Invest Northern Ireland grant. Executive Chairman Andrew Webb described the placing as "a pivotal moment", providing Capital "to take us beyond the critical milestone of dosing our first patient".
What could drive the stock next?
The most immediate catalyst is confirmation of the first patient treated. The company says it is fully funded to complete Part 1, designed to identify optimal dosing, validate safety and look for early efficacy signals such as progression-free survival. Any Part 1 read-out would be the first human data for the platform.
Additional site activations would de-risk recruitment. A partnering or licensing deal for docetaxel-ChemoSeed, which management has openly invited, would provide external validation and potentially non-dilutive cash. Interim results for the six months to 30 June 2026 are due in September, based on last year's timetable.
Risks investors should watch
CRISM is pre-revenue and consumed roughly £1.9m in 2025 with year-end cash of just £1.1m. The May 2026 raise and grants fund Part 1, but Part 2 and any prostate cancer trial will need more capital, and the company has returned to the market three times since June 2025. Further dilution is likely, and the 15p warrants only bring in cash if the shares rise well above the current level.
Clinical risk is high: glioblastoma has defeated many well-funded programmes, and an open-label, uncontrolled Part 1 will generate limited efficacy evidence. Recruitment in a rare, rapidly progressing cancer can be slow, and the timetable has already slipped. Governance is in transition, with Andrew Webb serving as Interim Executive Chair since Dr Nermeen Varawalla resigned in April 2026; a permanent Chair search is ongoing. Liquidity is thin: lse.co.uk showed a bid-offer spread of around 14% and a 52-week range of 8.25p to 18.25p. Insiders and a few institutions, including Miton at 9.47% and Mr Webb at 9.22%, hold a large share of the 79.2m shares in issue.
Outlook
CRISM has moved from an idea with grant support to a live Phase 2 trial with orphan drug status, an NHS site recruiting and, on its own account, enough funding to complete Part 1. Investors should watch for the first-patient announcement, the pace of enrolment, the September interim results and their cash figure, and any progress on partnering the prostate cancer asset. Whether the story is underestimated will depend on what the first human data show and whether the company can fund itself to that point without excessive dilution.






Please wait processing your request...